Michael Andrew Gillespie
Director/Board Member at Glixogen Therapeutics Ltd.
Network origin in Michael Andrew Gillespie first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA.
28
| Operating Division | Investment Managers | 28 |
Glixogen Therapeutics Ltd.
 Glixogen Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Glixogen Therapeutics Ltd. engages in the development of treatment to enhance remyelination in neurodegenerative disorders. The company was founded on October 11, 2018 and is headquartered in Ness Ziona, Israel.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Michael Andrew Gillespie via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Investment Managers | Chief Executive Officer Portfolio Manager-Equities Portfolio Manager-Equities Analyst-Equity Analyst-Equity Analyst-Equity Analyst-Equity Analyst-Equity | |
| VISTERRA INC | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| WAVE LIFE SCIENCES LTD. | Biotechnology | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | College/University | Doctorate Degree Doctorate Degree | |
| College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree Undergraduate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| Yale University | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| Princeton University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of Georgia | College/University | Undergraduate Degree | |
BIOCOM
 BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
| Ben-Gurion University of the Negev | College/University | Graduate Degree Doctorate Degree | |
| Xcellsyz Ltd. | Corporate Officer/Principal | ||
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| SPERO THERAPEUTICS, INC. | Biotechnology | Founder Director/Board Member Director/Board Member | |
| ALECTOR, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| SYNTHORX, INC. | Biotechnology | Director/Board Member Director/Board Member | |
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Investment Managers | Chief Executive Officer Director of Finance/CFO | |
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Suzhou Connect Biopharma Co. Ltd.
 Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Pharmaceuticals: Major | Director/Board Member | |
| VOR BIOPHARMA INC. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
BioMed Valley Discoveries, Inc.
 BioMed Valley Discoveries, Inc. Miscellaneous Commercial ServicesCommercial Services BioMed Valley Discoveries, Inc. is a biotechnology company that develops therapies for cancer, inflammation, and infectious disease. The private company is based in Kansas City, MO. The company was founded by Saurabh Saha. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Jnana Therapeutics, Inc.
 Jnana Therapeutics, Inc. BiotechnologyHealth Technology Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA. | Biotechnology | Founder Director/Board Member | |
Clear Creek Bio, Inc.
 Clear Creek Bio, Inc. Pharmaceuticals: MajorHealth Technology Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| LAVA THERAPEUTICS N.V. | Biotechnology | Director/Board Member | |
Nayan Therapeutics, Inc.
 Nayan Therapeutics, Inc. BiotechnologyHealth Technology Nayan Therapeutics, Inc. operates as a biotechnology company. It focuses on small molecule development for oscular disorders involving rod degeneration. The company is headquartered in Medfield, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
| ELIEM THERAPEUTICS, INC. | Biotechnology | Director/Board Member Founder | |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Pharmaceuticals: Major | Director/Board Member | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Santi Therapeutics, Inc.
 Santi Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Santi Therapeutics, Inc. provides pharmaceutical services. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Medical/Nursing Services | Director/Board Member Director/Board Member Chief Executive Officer | |
| PEPGEN INC. | Biotechnology | Director/Board Member Chairman | |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Miscellaneous Commercial Services | Chairman Chief Executive Officer Founder Director/Board Member | |
| DAY ONE BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| CONNECT BIOPHARMA HOLDINGS LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
| RESEARCH ALLIANCE CORP. II | Financial Conglomerates | Chief Executive Officer Founder Director of Finance/CFO | |
Aliada Therapeutics, Inc.
 Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Biotechnology | Chief Executive Officer Director/Board Member Director/Board Member | |
Superluminal Medicines Inc
 Superluminal Medicines Inc BiotechnologyHealth Technology Superluminal Medicines Inc is a generative biological and chemical company. The company is based in Boston, MA. The CEO of the company is Cony D'Cruz. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
Stylus Medicine, Inc.
 Stylus Medicine, Inc. Medical SpecialtiesHealth Technology Stylus Medicine, Inc. is a company focused on developing innovative solutions to combat diseases using cutting-edge genome engineering and chromatin regulation technologies. Stylus Medicine is based in Boston, MA. The company is backed by RA Ventures and Khosla Ventures. | Medical Specialties | Director/Board Member President |
Statistics
International
| United States | 40 |
| Israel | 4 |
| United Kingdom | 4 |
| China | 3 |
| Singapore | 2 |
Sectoral
| Health Technology | 31 |
| Consumer Services | 9 |
| Finance | 7 |
| Commercial Services | 4 |
| Health Services | 2 |
Operational
| Director/Board Member | 173 |
| Corporate Officer/Principal | 42 |
| Independent Dir/Board Member | 39 |
| Undergraduate Degree | 27 |
| Private Equity Investor | 26 |
Most connected contacts
| Insiders | |
|---|---|
| Joshua Resnick | 36 |
| Peter Kolchinsky | 32 |
| Risa Stack | 26 |
| Andrew Levin | 22 |
| Reza Halse | 18 |
| Derek DiRocco | 17 |
| Raj Shah | 16 |
| Matthew Hammond | 13 |
| Adam Rosenberg | 13 |
| Liana Patt | 11 |
| Tess Cameron | 11 |
| Zach Scheiner | 11 |
| Milind Deshpande | 11 |
| Jake Simson | 11 |
| Laura Tadvalkar | 10 |
- Stock Market
- Insiders
- Michael Andrew Gillespie
- Company connections
